Media

January 5 2022Regulatory

Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022 ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022 LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage

January 4 2022Regulatory

Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company

December 16 2021Regulatory

Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction

Study Supports Ongoing Phase 3 Program and Planned NDA Submission LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces ensifentrine met all safety

November 9 2021Regulatory

Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021 ENHANCE Phase 3 program on track to report top-line data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc

November 1 2021Regulatory

Verona Pharma Announces November 2021 Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the

October 26 2021Regulatory

Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and nine months ended September 30, 2021 on

View our latest materials to follow our progress in tackling respiratory diseases.

Corporate Presentation

Latest Videos

Ensifentrine (RPL554): Mechanism of action

Verona Pharma's novel COPD candidate "has the potential to significantly benefit patients," believes CMO Dr Kathleen Rickard

Filters

Email Alerts